Impact of guidance issued during COVID-19 to expand take-home doses of opioid agonist treatment (OAT) in Ireland: protocol for a population-based analysis of prescribing practices and patient outcomes 2018 to 2023 [version 2; peer review: 1 approved, 2 approved with reservations]

Background It is increasingly suggested that clinical guidelines and practices be updated to permanently expand relaxation around access to opioid agonist treatment (OAT) take-home doses after COVID-19. Despite a risk of OAT drug diversion, flexibility in take-home doses is valued by patients and as...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Suzi Lyons, Kathleen Bennett, Gráinne Cousins, Louise Durand, Andy O'Hara, Des Crowley, Eamon Keenan
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	F1000 Research Ltd 2025-04-01
סדרה:	HRB Open Research
נושאים:	Opioid Agonist Treatment Take-home dosing Opioid Use Disorder Covid-19 retention mortality eng
גישה מקוונת:	https://hrbopenresearch.org/articles/8-32/v2
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!